Picture loading failed.

Anti-IL2RA therapeutic antibody (Pre-made Daclizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Daclizumab (trade name Zinbryta) is a therapeutic humanized monoclonal antibody which was used for the treatment of adults with relapsing forms of multiple sclerosis (MS). Daclizumab works by binding to CD25, the alpha subunit of the IL-2 receptor of T-cells.

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-129-1mg 1mg 3090
GMP-Bios-ab-129-10mg 10mg 21890
GMP-Bios-ab-129-100mg 100mg 148000
GMP-Bios-ab-129-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-IL2RA therapeutic antibody (Pre-made Daclizumab biosimilar,Whole mAb)
INN Name Daclizumab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI Structure3nfs:HL/3nfp:HL:AB
99% SI StructureNone
95-98% SI StructureNone
Year Proposed1994
Year Recommended1998
CompaniesAbbVie;Biogen;Dana-Farber Cancer Institute;National Cancer Institute (USA);PDL BioPharma
Conditions ApprovedRenal transplant rejection
Conditions ActiveMultiple sclerosis
Conditions DiscontinuedAsthma;Graft-versus-host disease;Haematological malignancies;Immune-mediated uveitis;Liver transplant rejection;Psoriasis;Tropical spastic paraparesis;Type 1 diabetes mellitus;Ulcerative colitis
Development TechGS Gene Expression System